Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below Two Hundred Day Moving Average – Here’s Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.04 and traded as low as $6.78. Karyopharm Therapeutics shares last traded at $7.66, with a volume of 233,130 shares traded.

Analyst Ratings Changes

A number of equities analysts have issued reports on KPTI shares. Robert W. Baird reduced their target price on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. HC Wainwright raised their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Price Performance

The stock has a 50-day moving average price of $9.43 and a 200 day moving average price of $10.97. The company has a market cap of $63.40 million, a price-to-earnings ratio of -7.38 and a beta of 0.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. Sell-side analysts expect that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after buying an additional 36,922 shares during the last quarter. Silverarc Capital Management LLC grew its stake in Karyopharm Therapeutics by 6.7% in the fourth quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock valued at $403,000 after purchasing an additional 37,524 shares in the last quarter. Velan Capital Investment Management LP bought a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP grew its stake in Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).